ArticleClinical transplantation2026
Graft Outcomes in For-Cause Biopsy-Proven Recurrent IgA Nephropathy After Kidney Transplantation: Rare but Clinically Meaningful.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecurrent IgA nephropathy (IgAN) after kidney transplantation has been reported in up to 20%-60% of recipients, through incidence varies by surveillance strategy. We aimed to define the incidence and clinical impact of biopsy-proven recurrence IgAN in a single center cohort.
methodsWe performed retrospective review of renal allograft biopsies performed at UCLA between 2020 and 2025. A total of 1474 patients underwent kidney allograft biopsies for clinical reasons. 40 patients had biopsy-proven recurrent IgAN and were included in analysis. Clinical, laboratory and histopathologic features at recurrence were analyzed for association with graft failure using Kaplan-Meier. Time-to event analyses were performed using Cox regression.
resultBiopsy-proven recurrent IgAN was identified in 40 of 1474 for-cause biopsy recipients (2.7%). Graft failure occurred in 10 of 40 patients (25.0%) over a median follow-up of 5.57 years. Median time from recurrence to graft failure was 2.46 years. Graft loss was attributed primarily to recurrent IgAN in 7 patients (70.0%) and associated with rejection in 3 (30.0%). IFTA >50% was the only significant predictor of graft failure (HR 4.00, 95% CI 1.12-14.27; p = 0.03). Rising creatinine, proteinuria, hematuria, Asian race, and C3 bright deposition showed non-significant trends toward worse graft survival.
conclusionIn this for-cause biopsy cohort, clinically detected recurrent IgAN was associated with meaningful graft loss. Severe chronic injury at recurrence identified patients with poorer prognosis, although this likely reflects advanced nonspecific allograft damage rather than a recurrence-specific mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.